98%
921
2 minutes
20
The aim was to characterize differences in fecal consistency, and fecal microbiota and metabolome profiles in dogs with acute diarrhea (AD) treated with either fecal microbiota transplantation as enema (FMT; = 11) or oral metronidazole (MET; = 7) for 7 days. On days 0, 7, and 28 fecal samples were obtained. Fecal samples from healthy dogs (HC; = 14) were used for comparison. Samples were analyzed by the previously validated qPCR based canine Dysbiosis Index (DI; increased values indicate microbiota dysbiosis) and 16S rRNA gene sequencing. The fecal metabolome was analyzed using a previously validated targeted canine assay for fecal unconjugated bile acids, and untargeted metabolomics. Fecal consistency improved significantly in dogs treated with FMT and MET by day 7 and day 28 ( < 0.01) compared to day 0. However, on day 28 fecal consistency was significantly better in FMT compared to MET ( = 0.040). At day 0, dogs with AD had an altered microbiota indicated by significantly increased DI, decreased alpha-diversity, and altered beta-diversity. In the FMT group, the DI decreased over time, while MET led to a significant increase in the dysbiosis index at day 7 and 28 compared to FMT. Sequencing data revealed that in FMT microbial diversity and beta-diversity was similar to HC at day 28, while in MET these parameters were still significantly different from HC. In dogs treated with FMT, a decrease in cholic acid and the percentage of primary bile acids was observed, whereas treatment with metronidazole led to an increase in cholic acid at day 7 and an increase in percentage of primary bile acids over time. Based on untargeted metabolomics, dogs with AD had an altered fecal metabolome compared to HC. Dogs treated with FMT clustered closer to HC at day 28, while dogs treated with MET did not. In this pilot study, dogs with AD had significant differences in fecal microbiota and metabolome profiles. Dogs treated with MET still had altered microbial and metabolic profiles at day 28 compared to dogs treated with FMT or healthy dogs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182012 | PMC |
http://dx.doi.org/10.3389/fvets.2020.00192 | DOI Listing |
Front Vet Sci
August 2025
Fitzpatrick Referrals, Neurology Service, Eashing, United Kingdom.
Pug dogs are predisposed to thoracolumbar myelopathy associated with vertebral articular process dysplasia, suggesting a biomechanical etiology. While surgery is commonly pursued, long-term outcomes remain poorly defined. This retrospective descriptive case series reports on seven Pug dogs that underwent surgical treatment for thoracolumbar myelopathy and were followed up for at least 7 years postoperatively.
View Article and Find Full Text PDFKlin Mikrobiol Infekc Lek
June 2025
Institute of Infectious Diseases and Microbiology, Faculty of Veterinary Medicine, University of Veterinary Sciences Brno,Czech Republic, e-mail:
Capnocytophaga spp. are typical members of the commensal microflora of the oral cavity. However, C.
View Article and Find Full Text PDFAm J Vet Res
September 2025
Veterinary Emergency Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Research Institute for Veterinary Science, Seoul National University, Seoul, South Korea.
Objective: To determine whether high-flow nasal oxygen therapy (HFNOT) induces changes in esophageal pressure, a surrogate for intrathoracic pressure, and to evaluate the associated cardiovascular and respiratory effects in healthy dogs.
Methods: A prospective, randomized study was conducted in 6 healthy Beagles. Anesthesia was induced and maintained using alfaxalone total IV anesthesia.
J Am Vet Med Assoc
September 2025
4CENTAURO Research Group, School of Veterinary Medicine, Faculty of Agrarian Sciences, Universidad de Antioquia, Medellín, Colombia.
Background: Canine osteoarthritis (OA) is a progressive degenerative joint disease causing pain and mobility impairment. While the disease is incurable, multimodal management including regenerative therapies like platelet-rich plasma (PRP) can improve outcomes. However, protocol standardization remains a challenge.
View Article and Find Full Text PDFVet Res Commun
September 2025
Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin, 150030, China.
Background: Canine parvovirus (CPV) poses a severe threat to canine health, necessitating the development of safer and more effective vaccines. While traditional vaccines carry risks of virulence reversion and environmental contamination, subunit vaccines-especially neutralizing epitope vaccines-offer promising alternatives by eliciting targeted immune responses with enhanced safety.
Methods: We employed bacterial display technology to express 11 overlapping CPV VP2 gene fragments on the periplasmic membrane of E.